StockNews.com Downgrades Prestige Consumer Healthcare (NYSE:PBH) to Hold

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Thursday.

PBH has been the topic of several other research reports. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Jefferies Financial Group restated a “hold” rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research report on Monday, December 9th. Finally, DA Davidson reissued a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $85.25.

Prestige Consumer Healthcare Stock Up 1.4 %

Shares of NYSE:PBH traded up $1.11 during mid-day trading on Thursday, reaching $78.31. 327,709 shares of the stock were exchanged, compared to its average volume of 294,271. The company has a market cap of $3.87 billion, a P/E ratio of 19.05, a P/E/G ratio of 2.08 and a beta of 0.51. Prestige Consumer Healthcare has a one year low of $58.22 and a one year high of $86.36. The stock’s 50 day simple moving average is $80.56 and its 200-day simple moving average is $74.41. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company’s revenue for the quarter was down .9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.07 EPS. As a group, equities research analysts predict that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 9,885 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the sale, the senior vice president now owns 18,835 shares in the company, valued at $1,543,904.95. The trade was a 34.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider William P’pool sold 8,987 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the transaction, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock worth $3,187,300 over the last ninety days. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of institutional investors have recently modified their holdings of the business. Quest Partners LLC increased its position in Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after acquiring an additional 424 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in shares of Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after purchasing an additional 433 shares in the last quarter. nVerses Capital LLC increased its holdings in shares of Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the period. Huntington National Bank raised its position in shares of Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after buying an additional 181 shares in the last quarter. Finally, International Assets Investment Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 7,112.5% in the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after buying an additional 1,138 shares during the period. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.